Evidence map›Paper›PMID 24676590›Full record

ReviewZeitschrift fur Rheumatologie2014

[Safety of antirheumatic drug treatment in the elderly].

K Krüger, A Strangfeld, C Kneitz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

K KrügerRheumatologisches Praxiszentrum, St. Bonifatius Str. 5, 81541, München, Deutschland. klaus.krueger@med.uni-muenchen.de.
A StrangfeldDeutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Deutschland.
C KneitzKlinik für Innere Medizin II, Rheumatologie/Immunologie, Rheumazentrum, Klinikum Südstadt Rostock, Rostock, Deutschland.
German Rheumatism Research Centre · DEKlinikum Südstadt Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mainly due to the general demographic changes and decreasing mortality in rheumatic diseases based on therapeutic progress, the proportion of older patients treated by rheumatologists is growing. Drug treatment in the elderly, however, harbors certain risks including age-specific pharmacokinetic features and high rates of multimorbidity and polypharmacy resulting in a risk of drug interactions and adherence problems. Nevertheless, older patients suffering from rheumatic diseases ought to be treated with the same intensity and same targets as the younger counterparts. Bearing all these facts in mind it is a balancing act for rheumatologists to find an optimal treatment for the individual elderly patient. Fear of risks should not lead to hesitant use of drugs leaving these patients alone with treatment deficits, as some studies have suggested.

Indexed as

AgedAged, 80 and overAntirheumatic AgentsChemical and Drug Induced Liver InjuryCommunicable DiseasesDose-Response Relationship, DrugDrug InteractionsFemaleHumansImmune System DiseasesImmunosuppressive AgentsKidney DiseasesMaleRheumatic DiseasesAntirheumatic AgentsImmunosuppressive AgentsAntirheumatic drugsDrug interactionsDrug safetyDrug treatmentElderly patients

Identifiers

PMID24676590
OpenAlexW160420294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.